Health Tech Capitol | Promega cancer treatment screening test expected to expand company
16863
post-template-default,single,single-post,postid-16863,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Promega cancer treatment screening test expected to expand company

07 Nov Promega cancer treatment screening test expected to expand company

Posted at 10:26h in Uncategorized by
0 Likes

A genetic test developed by Promega Corp. could help doctors decide which patients get a widely used cancer drug, following a collaboration announced Wednesday by Promega and drug maker Merck.

The development, pending federal approval, is expected to propel Promega’s growth and account for 10% to 20% of the company’s business in five years, Promega CEO Bill Linton said. Promega has 1,682 employees, including 1,055 at its Fitchburg headquarters.

“It’s something that we think is transformational in the field of human therapy and specifically cancer therapies,” Linton said.

Read more at the Wisconsin State Journal

No Comments

Sorry, the comment form is closed at this time.